Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PD
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The general aim of this study is to obtain long-term safety and tolerability data on
pramipexole extended release (ER), in daily doses from 0.375mg to 4.5mg once daily (qd), in
patients who have previously completed a pramipexole double-blind study in advanced
Parkinson's disease (PD) (248.525 trial).